A project to develop biomarker-guided personalised vaccines for patients with glioblastoma has received €6 million in European Union funding under the Framework 7 programme. Immatics Biotechnologies GmbH is the coordinator. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals Research & University News
